Zoetis Inc. (NYSE:ZTS) EVP Sells $55,804.68 in Stock

Zoetis Inc. (NYSE:ZTS) EVP Roxanne Lagano sold 326 shares of the firm’s stock in a transaction on Tuesday, February 11th. The shares were sold at an average price of $171.18, for a total transaction of $55,804.68. Following the sale, the executive vice president now owns 16,107 shares in the company, valued at $2,757,196.26. The trade was a 1.98 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink.

Zoetis Trading Up 1.5 %

Shares of NYSE ZTS opened at $174.47 on Wednesday. Zoetis Inc. has a 1-year low of $144.80 and a 1-year high of $200.53. The company has a debt-to-equity ratio of 1.26, a current ratio of 3.69 and a quick ratio of 2.27. The business’s 50 day moving average is $169.16 and its two-hundred day moving average is $179.15. The stock has a market capitalization of $78.72 billion, a P/E ratio of 32.80, a PEG ratio of 2.77 and a beta of 0.90.

Zoetis Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, June 3rd. Shareholders of record on Monday, April 21st will be paid a $0.50 dividend. This represents a $2.00 annualized dividend and a yield of 1.15%. The ex-dividend date is Monday, April 21st. Zoetis’s payout ratio is currently 37.59%.

Analyst Ratings Changes

A number of research firms have commented on ZTS. Stifel Nicolaus dropped their price target on Zoetis from $210.00 to $180.00 and set a “buy” rating for the company in a research note on Tuesday, January 7th. UBS Group began coverage on shares of Zoetis in a research report on Monday, December 9th. They set a “neutral” rating and a $196.00 target price for the company. Leerink Partnrs upgraded shares of Zoetis to a “strong-buy” rating in a report on Monday, December 2nd. Leerink Partners started coverage on shares of Zoetis in a report on Monday, December 2nd. They set an “outperform” rating and a $215.00 price objective for the company. Finally, Morgan Stanley reduced their target price on Zoetis from $248.00 to $243.00 and set an “overweight” rating on the stock in a report on Wednesday, January 29th. One equities research analyst has rated the stock with a hold rating, ten have assigned a buy rating and two have assigned a strong buy rating to the company. According to data from MarketBeat.com, the stock currently has an average rating of “Buy” and a consensus price target of $214.00.

Institutional Inflows and Outflows

Large investors have recently modified their holdings of the business. Atlantic Edge Private Wealth Management LLC lifted its stake in shares of Zoetis by 482.8% during the 4th quarter. Atlantic Edge Private Wealth Management LLC now owns 169 shares of the company’s stock worth $28,000 after acquiring an additional 140 shares during the last quarter. Rakuten Securities Inc. increased its stake in Zoetis by 5,533.3% in the fourth quarter. Rakuten Securities Inc. now owns 169 shares of the company’s stock worth $28,000 after purchasing an additional 166 shares during the period. Darwin Wealth Management LLC bought a new stake in shares of Zoetis during the third quarter worth $31,000. First Personal Financial Services purchased a new stake in shares of Zoetis during the third quarter valued at $33,000. Finally, Capital Performance Advisors LLP bought a new position in shares of Zoetis in the third quarter worth about $33,000. Hedge funds and other institutional investors own 92.80% of the company’s stock.

Zoetis Company Profile

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.